Literature DB >> 7418969

The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects.

A M Molloy, J Ardill, G H Tomkin.   

Abstract

Gastric acid secretion and gastrointestinal hormone levels were measured in healthy non-diabetic subjects after metformin treatment (1.5 g/day). The maximum acid output was increased from 15.7 +/- 3.9 mmol/h (mean +/- SEM) to 30.0 +/- 7.1 mmol/h (p < 0.05) and the peak acid output was increased from 16.4 +/- 4.1 mmol/h to 31.7 +/- 7.2 mmol/h (p < 0.05) after two weeks treatment. Serum insulin, gastric inhibitory polypeptide and secretin levels were normal. After treatment for one week, however, there was a significant increase in fasting vasoactive intestinal peptide (VIP) from 83 +/- 6 ng/1 to 102 +/- 9 ng/1 (p < 0.02) and in stimulated VIP from 58 +/- 5 ng/1 to 79 +/- 5 ng/1 (p < 0.05). Stimulated glucagon-like immunoreactivity (GLI) was also increased from 82 +/- 10 ng/1 to 174 +/- 24 ng/1 (p < 0.01) after one week's treatment. It is suggested that metformin acts as a weak histamine agonist.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7418969     DOI: 10.1007/bf00421851

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

1.  The effect of phenformin upon the plasma pancreatic and gut glucagon-like immunoreactivity in diabetics.

Authors:  A Czyzyk; L G Heding; B Malczewski; E Miedzinska
Journal:  Diabetologia       Date:  1975-04       Impact factor: 10.122

2.  Potential histamine H2-receptor antagonists. 2. N-alpha-Guanylhistamine.

Authors:  G J Durant; M E Parsons; J W Black
Journal:  J Med Chem       Date:  1975-08       Impact factor: 7.446

Review 3.  Gastrointestinal hormones.

Authors:  S R Bloom
Journal:  Int Rev Physiol       Date:  1977

4.  Pentagastrin as a stimulant of maximal gastric acid response in man. A multicentre pilot study.

Authors: 
Journal:  Lancet       Date:  1967-02-11       Impact factor: 79.321

5.  Tissue distribution and excretion of phenformin in normal and diabetic animals.

Authors:  H Hall; G Ramachander; J M Glassman
Journal:  Ann N Y Acad Sci       Date:  1968-03-26       Impact factor: 5.691

6.  Receptors mediating some actions of histamine.

Authors:  A S Ash; H O Schild
Journal:  Br J Pharmacol Chemother       Date:  1966-08

7.  Anti-gastric acid secretory effect of phenformin--a preliminary report.

Authors:  R S Diniz; G J Abraham; S S Ahmed
Journal:  Eur J Pharmacol       Date:  1972-09       Impact factor: 4.432

8.  Influence of feeding and sham feeding upon serum gastrin and gastric acid secretion in control subjects and duodenal ulcer patients.

Authors:  G Mayer; R Arnold; G Feurle; K Fuchs; H Ketterer; N S Track; W Creutzfeldt
Journal:  Scand J Gastroenterol       Date:  1974-11       Impact factor: 2.423

9.  Biguanides and intestinal absorptive function.

Authors:  W F Caspary
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1977-12

10.  Malabsorption of vitamin B12 in diabetic patients treated with phenformin: a comparison with metformin.

Authors:  G H Tomkin
Journal:  Br Med J       Date:  1973-09-29
  10 in total
  7 in total

1.  Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.

Authors:  Heidi N Boyda; Ric M Procyshyn; Lurdes Tse; Erin Hawkes; Chen H Jin; Catherine C Y Pang; William G Honer; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2012-11       Impact factor: 6.186

2.  A Metformin-Responsive Metabolic Pathway Controls Distinct Steps in Gastric Progenitor Fate Decisions and Maturation.

Authors:  Zhi-Feng Miao; Mahliyah Adkins-Threats; Joseph R Burclaff; Luciana H Osaki; Jing-Xu Sun; Yan Kefalov; Zheng He; Zhen-Ning Wang; Jason C Mills
Journal:  Cell Stem Cell       Date:  2020-04-02       Impact factor: 24.633

3.  Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy.

Authors:  J F Adams; J S Clark; J T Ireland; C M Kesson; W S Watson
Journal:  Diabetologia       Date:  1983-01       Impact factor: 10.122

Review 4.  Incretin-based therapies in type 2 diabetes mellitus.

Authors:  Chee W Chia; Josephine M Egan
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958

5.  Prediction and validation of enzyme and transporter off-targets for metformin.

Authors:  Sook Wah Yee; Lawrence Lin; Matthew Merski; Michael J Keiser; Aakash Gupta; Youcai Zhang; Huan-Chieh Chien; Brian K Shoichet; Kathleen M Giacomini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-03       Impact factor: 2.745

6.  Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine.

Authors:  L Pénicaud; Y Hitier; P Ferré; J Girard
Journal:  Biochem J       Date:  1989-09-15       Impact factor: 3.857

7.  Metformin causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state.

Authors:  Philipp Schommers; Anna Thurau; Insa Bultmann-Mellin; Maria Guschlbauer; Andreas R Klatt; Jan Rozman; Martin Klingenspor; Martin Hrabe de Angelis; Jens Alber; Dirk Gründemann; Anja Sterner-Kock; Rudolf J Wiesner
Journal:  Mol Metab       Date:  2017-05-05       Impact factor: 7.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.